Reported revenue is lumpy and gross margin figures lack structural meaning, while R&D-driven operating losses of -$147.2M in 2026Q3 show costs outpacing any revenue offset.
Kymera Therapeutics, Inc. (KYMR) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 102.22M | 39.2M | 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | 2.93M | 0 |
| Revenue Growth % | 133.74% | -16.72% | -40.11% | 67.84% | -35.71% | 114% | 1059.99% | - | - |
| Cost of Goods Sold | -76.18M | 0 | 0 | 0 | 0 | 0 | 0 | 825K | 205K |
| COGS % of Revenue | - | - | - | - | - | - | - | 28.12% | - |
| Gross Profit | 178.4M | 39.2M | 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | 2.11M | -205K |
| Gross Margin % | 174.52% | 100% | 100% | 100% | 100% | 100% | 100% | 71.88% | - |
| Gross Profit Growth % | - | -16.72% | -40.11% | 67.84% | -35.71% | 114% | 1513.75% | 1128.78% | - |
| Operating Expenses | 583.29M | 388.6M | 308.71M | 244.12M | 208.08M | 173.36M | 80.34M | 45.14M | 21.45M |
| OpEx % of Revenue | - | 991.33% | 655.82% | 310.62% | 444.37% | 238.03% | 236.05% | 1538.48% | - |
| Selling, General & Admin | 77.15M | 68.2M | 63.53M | 55.04M | 43.83M | 36.34M | 18.23M | 7.98M | 3.77M |
| SG&A % of Revenue | - | 173.98% | 134.97% | 70.03% | 93.61% | 49.9% | 53.57% | 272.02% | - |
| Research & Development | 430.01M | 316.6M | 240.25M | 189.08M | 164.25M | 137.02M | 62.1M | 37.16M | 17.68M |
| R&D % of Revenue | - | 807.65% | 510.38% | 240.59% | 350.76% | 188.13% | 182.48% | 1266.46% | - |
| Other Operating Expenses | 1000K | 3.8M | 4.92M | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -404.89M | -349.4M | -261.63M | -165.53M | -161.26M | -100.53M | -46.3M | -42.2M | -21.45M |
| Operating Margin % | -396.08% | -891.33% | -555.82% | -210.62% | -344.37% | -138.03% | -136.05% | -1438.48% | - |
| Operating Income Growth % | - | -33.54% | -58.06% | -2.65% | -60.41% | -117.11% | -9.71% | -96.75% | - |
| EBITDA | -396.78M | -341.09M | -254.26M | -161.97M | -158.28M | -98.13M | -44.54M | -41.38M | -21.25M |
| EBITDA Margin % | -388.15% | -870.12% | -540.16% | -206.08% | -338.02% | -134.74% | -130.87% | -1410.36% | - |
| EBITDA Growth % | -22.47% | -34.15% | -56.99% | -2.33% | -61.29% | -120.32% | -7.64% | -94.77% | - |
| D&A (Non-Cash Add-back) | 8.11M | 8.31M | 7.37M | 3.56M | 2.98M | 2.4M | 1.76M | 825K | 205K |
| EBIT | -349.42M | -311.37M | -223.61M | -146.77M | -154.63M | -100.04M | -45.48M | -41.2M | -21.45M |
| Net Interest Income | 55.19M | 37.78M | 37.78M | 18.57M | 6.45M | 313K | 711K | 959K | 0 |
| Interest Income | 55.47M | 38.03M | 38.03M | 18.76M | 6.62M | 488K | 826K | 1M | 0 |
| Interest Expense | 273K | 249K | 249K | 196K | 176K | 175K | 115K | 46K | 16K |
| Other Income/Expense | 55.19M | 37.78M | 37.78M | 18.57M | 6.45M | 313K | 711K | 959K | -16K |
| Pretax Income | -349.7M | -311.62M | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Pretax Margin % | -342.09% | -794.96% | -475.57% | -186.99% | -330.6% | -137.6% | -133.96% | -1405.79% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 43.86K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.2% |
| Net Income | -349.47M | -311.4M | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.29M | -21.47M |
| Net Margin % | -341.87% | -794.39% | -475.57% | -186.99% | -330.6% | -137.6% | -133.96% | -1407.36% | - |
| Net Income Growth % | -18.42% | -39.11% | -52.32% | 5.07% | -54.47% | -119.81% | -10.42% | -92.35% | - |
| Net Income (Continuing) | -349.7M | -311.62M | -223.86M | -146.96M | -154.81M | -100.22M | -45.59M | -41.25M | -21.47M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.49 | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -0.99 | -0.93 | -0.48 |
| EPS Growth % | -1.11% | -23.83% | -18.25% | 12.2% | -37.32% | -111.11% | -6.45% | -93.75% | - |
| EPS (Basic) | - | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | -0.99 | -0.93 | -0.48 |
| Diluted Shares Outstanding | 100.1M | 84.39M | 75.04M | 58.37M | 53.93M | 47.99M | 44.56M | 44.53M | 44.53M |
| Basic Shares Outstanding | 100.1M | 84.39M | 75.04M | 58.37M | 53.93M | 47.99M | 44.56M | 44.53M | 44.53M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying KYMR stock.
For fiscal year 2025, Kymera Therapeutics, Inc. (KYMR) reported total revenue of $39.2M.
Kymera Therapeutics, Inc. (KYMR) reported a net loss of $311.4M for the fiscal year ending 2025.
Kymera Therapeutics, Inc. (KYMR) reported an operating income of $-349.4M, resulting in an operating profit margin of -891.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Kymera Therapeutics, Inc. (KYMR) generated $39.2M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Sustained operating losses persist
Metrics are mathematically derived from official filings.
Lumpy Revenue Masks Persistent Losses
Based on reported figures, KYMR's quarterly revenue swung from $2.8M in 2025Q3 to $65.0M in 2026Q2, a pattern that suggests collaboration or milestone recognition rather than recurring product sales and warrants further investigation.
The revenue series is highly irregular, with several quarters near zero and a single $65.0M quarter in 2026Q2, which implies revenue is driven by lumpy licensing or collaboration events rather than steady commercial demand. Because operating expenses remained between roughly $100M and $147M per quarter throughout the period, even the strongest revenue quarter did not produce a sustained operating profit. Investors should monitor whether future revenue reflects repeatable partnership income or one-time recognition.
Gross Margin Figures Lack Structural Meaning
As reported in financial statements, KYMR's gross margin oscillates between roughly -26% and 100% with no COGS in most periods, so the metric appears to reflect collaboration accounting rather than product unit economics.
With cost of goods sold reported as zero in most quarters and negative in others, gross margin does not behave as a conventional cost-of-sales measure for this business. The more informative signal is operating margin, which remained deeply negative across all ten quarters, including -198.5% in 2024Q2 and -116.3% in 2026Q2. Analysts should treat gross margin as unreliable for valuation and focus on the operating expense base relative to collaboration revenue.
R&D Spending Drives the Cost Base
According to reported SEC filings, KYMR's R&D expense rose from $59.2M in 2024Q2 to $128.5M in 2026Q3, comprising the overwhelming majority of its operating cost structure and signaling sustained clinical investment.
R&D accounts for the large majority of total spending, while SG&A has stayed comparatively flat between roughly $15M and $21M per quarter, indicating disciplined general and administrative costs relative to research intensity. The more than doubling of R&D over the period suggests management is prioritizing pipeline advancement, which may be appropriate for a clinical-stage biotech but raises the funding requirement implied by the current loss rate. Stock-based compensation of roughly $14M to $19M per quarter is also a meaningful portion of operating expense.
Operating Losses Widen Despite Revenue Gains
Based on KYMR's reported figures, operating loss expanded from -$50.9M in 2024Q2 to -$147.2M in 2026Q3, indicating that cost growth has outpaced any revenue-driven offset rather than showing operating leverage.
Operating income has deteriorated as R&D expansion outweighed revenue growth, meaning the business is not exhibiting positive operating leverage at current revenue levels. Even when revenue reached $65.0M in 2026Q2, the operating loss remained at -$75.6M, which suggests the breakeven revenue level sits well above recent collaboration income. This pattern warrants further investigation into the timing and magnitude of future milestone receipts relative to planned spending.
Bear Case Centers on Cash Burn Duration
The strongest challenge to KYMR's income statement is that quarterly net losses of $60M to $130M appear unsustainable without recurring revenue, potentially pressuring future financing terms.
Short-sellers would likely emphasize that the company has not reported a profitable quarter in the ten-quarter window, and that revenue spikes do not offset a cost base that has grown toward $147M per quarter. Dilution is a plausible inference given EPS of -$1.32 in 2026Q3 and the loss scale, though the provided data does not disclose cash balances or financing arrangements, so this conclusion remains an inference requiring further investigation. The bullish counter is that R&D investment may be building a pipeline with asset value not captured in current income figures.